NZ583192A - Methods for treating dependence - Google Patents

Methods for treating dependence

Info

Publication number
NZ583192A
NZ583192A NZ583192A NZ58319208A NZ583192A NZ 583192 A NZ583192 A NZ 583192A NZ 583192 A NZ583192 A NZ 583192A NZ 58319208 A NZ58319208 A NZ 58319208A NZ 583192 A NZ583192 A NZ 583192A
Authority
NZ
New Zealand
Prior art keywords
cocaine
compound
inhibitor
patient
agonist
Prior art date
Application number
NZ583192A
Other languages
English (en)
Inventor
Tom Woiwode
Mark Moran
Lesley Pickford
Original Assignee
Biotie Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotie Therapies Inc filed Critical Biotie Therapies Inc
Publication of NZ583192A publication Critical patent/NZ583192A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
NZ583192A 2007-08-06 2008-08-06 Methods for treating dependence NZ583192A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93532307P 2007-08-06 2007-08-06
US95655507P 2007-08-17 2007-08-17
US96059107P 2007-10-04 2007-10-04
PCT/US2008/072357 WO2009021055A1 (en) 2007-08-06 2008-08-06 Methods for treating dependence

Publications (1)

Publication Number Publication Date
NZ583192A true NZ583192A (en) 2012-06-29

Family

ID=40341713

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ583192A NZ583192A (en) 2007-08-06 2008-08-06 Methods for treating dependence

Country Status (16)

Country Link
US (3) US20090041800A1 (enExample)
EP (2) EP3251670A1 (enExample)
JP (5) JP2010535801A (enExample)
CN (2) CN106983747A (enExample)
AU (1) AU2008283903B2 (enExample)
BR (1) BRPI0815089A2 (enExample)
CA (1) CA2695372C (enExample)
CO (1) CO6260015A2 (enExample)
ES (1) ES2638190T3 (enExample)
IL (1) IL257418A (enExample)
MX (4) MX391921B (enExample)
NZ (1) NZ583192A (enExample)
PH (1) PH12015502210A1 (enExample)
RU (1) RU2491067C2 (enExample)
SG (2) SG10201705968RA (enExample)
WO (1) WO2009021055A1 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201705968RA (en) * 2007-08-06 2017-08-30 Biotie Therapies Inc Methods for treating dependence
WO2010124089A2 (en) * 2009-04-22 2010-10-28 Synosia Therapeutics, Inc. Methods for treating dependence
US9804149B2 (en) * 2012-10-10 2017-10-31 Bio-Rad Laboratories, Inc. Patient-based results display
AU2014306759B2 (en) 2013-08-12 2018-04-26 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
EP3082816B1 (en) 2013-12-20 2019-03-20 Indivior UK Limited Intranasal naloxone compositions and methods of making and using same
EP3169315B1 (en) 2014-07-17 2020-06-24 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
US20160106737A1 (en) 2014-10-20 2016-04-21 Pharmaceutical Manufacturing Research Services, Inc. Extended Release Abuse Deterrent Liquid Fill Dosage Form
US20170235908A1 (en) * 2015-11-15 2017-08-17 Oriah Behaviorial Health, Inc. Systems and Methods for Managing and Treating Substance Abuse Addiction
AU2018319592B2 (en) 2017-08-20 2024-06-27 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
US11844859B2 (en) 2017-08-20 2023-12-19 Nasus Pharma Ltd. Dry powder compositions for intranasal delivery
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12459965B2 (en) 2017-10-09 2025-11-04 Compass Pathfinder Limited Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use
CN108066355A (zh) * 2017-12-28 2018-05-25 宁夏恩多芬科技有限公司 Nitrous Oxide作为治疗神经官能症的用途
FR3093419B1 (fr) * 2019-03-08 2021-06-18 Univ Grenoble Alpes Composition et procédé associé de mesure de l’observance thérapeutique
JP2022529781A (ja) 2019-04-17 2022-06-24 コンパス パスファインダー リミテッド サイロシビンによるうつ病及び他の様々な障害の治療
EP4180037A1 (en) * 2019-11-07 2023-05-17 Small Pharma Ltd Method of synthesis
US11806320B2 (en) 2020-02-19 2023-11-07 Endo Ventures Limited Isoproterenol compositions and methods
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN116528747A (zh) * 2020-08-17 2023-08-01 纽约市哥伦比亚大学理事会 神经黑色素敏感性mri作为多巴胺功能的生物标志物的用途
JP7753359B2 (ja) * 2020-10-24 2025-10-14 ユニヴェルシテートスピタル バーゼル ヒト血漿中のリゼルギン酸ジエチルアミド（ｌｓｄ）及び２，３－ジヒドロ－３－ヒドロキシ－２－オキソリセルギド（ｏ－ｈ－ｌｓｄ）を定量化するための方法
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
CN112690771B (zh) * 2020-12-09 2022-05-24 华南理工大学 一种利用线性回归模型的人脸视频心率检测方法
MX2023009703A (es) 2021-03-11 2023-08-29 Terran Biosciences Inc Sistemas, dispositivos y metodos para la armonizacion de conjuntos de datos de imaginologia, que incluye biomarcadores.
CN113017632B (zh) * 2021-03-17 2022-11-11 陈思 一种智慧校园心理咨询辅助方法及系统
EP4486448A1 (en) 2022-03-04 2025-01-08 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
IL319304A (en) 2022-09-16 2025-04-01 Jiangsu Yahong Meditech Co Ltd Polymorphic form of addition salt of nafixit acid, method for its preparation and use
WO2024178082A2 (en) * 2023-02-22 2024-08-29 Freedom Biosciences, Inc. Composition of opioid receptor modulator and mdma for use thereof
CN120754106B (zh) * 2025-09-02 2025-12-09 合肥工业大学 化合物sch23390在制备治疗铅中毒药物中的应用

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE91891T1 (de) * 1987-10-07 1993-08-15 Matrix Technologies Inc Pharmazeutische zusammensetzung fuer die behandlung der kokainsucht.
US5593367A (en) * 1995-08-18 1997-01-14 Deere & Company Switchable ignition and starter control system
CA2247468A1 (en) * 1996-02-23 1997-08-28 Mark Froimowitz Selective d1 dopamine receptor agonists and partial agonists/antagonists
US5958896A (en) * 1997-08-08 1999-09-28 The Mclean Hospital Cytidine-containing and cytosine-containing compounds as treatments for stimulant exposure
US6541520B1 (en) * 1998-08-05 2003-04-01 Brookhaven Science Associates Treatment of addiction and addiction-related behavior
ATE338575T1 (de) * 2001-01-17 2006-09-15 Hythiam Inc Verwendung von flumazenil bei der entwicklung eines arzneimittels zur behandlung von alkoholabhängigkeit
WO2002072006A2 (en) * 2001-03-07 2002-09-19 The Mclean Hospital Corporation METHODS AND REAGENTS FOR IDENTIFYING COMPOUNDS AND MUTATIONS THAT MODULATE DOPAMINE β-HYDROXYLASE ACTIVITY
SE0104388D0 (sv) * 2001-12-27 2001-12-27 Pharmacia Ab New formulation and use and manufacture thereof
WO2004075916A1 (en) * 2003-02-27 2004-09-10 Shirankai Kyoto University Faculty Of Medicine Alumni Association Inc. Pharmaceutical composition for treatment of drug dependence
RU2252756C1 (ru) * 2003-12-23 2005-05-27 Хохлов Александр Петрович Препарат против алкоголизма и наркомании, способ получения такого препарата
AU2008229203B2 (en) * 2007-03-16 2014-05-29 Emory University Methods and compositions for treatment of drug addiction
US20090054414A1 (en) * 2007-07-23 2009-02-26 Synosia Therapeutics Rufinamide for the Treatment of Post-Traumatic Stress Disorder
EP2182803A4 (en) * 2007-07-23 2010-09-01 Synosia Therapeutics (4-METHOXY-7-MORPHOLIN-4-YL-BENZOTHIAZOL-2-YL) -AMIDE 4-HYDROXY-4-METHYL-PIPERIDINE-1-CARBOXYLIC ACID FOR TREATING POST-TRAUMATIC STRESS DISORDER
SG183069A1 (en) * 2007-07-23 2012-08-30 Synosia Therapeutics Treatment of post-traumatic stress disorder
SG10201705968RA (en) 2007-08-06 2017-08-30 Biotie Therapies Inc Methods for treating dependence
WO2009069669A1 (ja) 2007-11-26 2009-06-04 Bridgestone Corporation 銅－亜鉛合金電気めっき浴およびこれを用いためっき方法

Also Published As

Publication number Publication date
ES2638190T3 (es) 2017-10-19
MX2010001390A (es) 2010-08-02
MX391921B (es) 2025-03-21
US20200383951A1 (en) 2020-12-10
CA2695372C (en) 2013-01-22
EP2182804B1 (en) 2017-05-24
SG183696A1 (en) 2012-09-27
JP2014148551A (ja) 2014-08-21
JP2020114883A (ja) 2020-07-30
WO2009021055A1 (en) 2009-02-12
MX357542B (es) 2018-07-13
CA2695372A1 (en) 2009-02-12
IL257418A (en) 2018-04-30
CN101815438A (zh) 2010-08-25
MX2022001510A (es) 2022-08-11
BRPI0815089A2 (pt) 2014-09-30
JP2018154645A (ja) 2018-10-04
AU2008283903B2 (en) 2014-01-16
US10561638B2 (en) 2020-02-18
CO6260015A2 (es) 2011-03-22
RU2491067C2 (ru) 2013-08-27
US20140099336A1 (en) 2014-04-10
EP2182804A1 (en) 2010-05-12
US20090041800A1 (en) 2009-02-12
PH12015502210A1 (en) 2017-04-10
SG10201705968RA (en) 2017-08-30
JP2016210798A (ja) 2016-12-15
CN106983747A (zh) 2017-07-28
EP3251670A1 (en) 2017-12-06
JP2010535801A (ja) 2010-11-25
AU2008283903A1 (en) 2009-02-12
EP2182804A4 (en) 2010-12-22
RU2010108249A (ru) 2011-09-20

Similar Documents

Publication Publication Date Title
RU2010108249A (ru) Способы лечения зависимости
JP2010535801A5 (enExample)
Stack et al. Monoamine oxidase inhibitors and anaesthesia: a review
US20200368225A1 (en) Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of depression, anxiety, and neurodegenerative disorders
JP6332651B2 (ja) 神経疾患治療のためのデキストロメトルファンおよびキニジンを含む薬剤組成物
WO2007084424A2 (en) Treatment of substance abuse
US20060258711A1 (en) Treatment of drug abuse
JP5491475B2 (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
US12257233B2 (en) Methods
Rehman et al. Clinical efficacy and safety profile of lofexidine hydrochloride in treating opioid withdrawal symptoms: a review of literature
Quintero et al. Ketamine in clinical practice: transitioning from anesthetic agent to psychiatric therapeutic
Yoon et al. Antinociceptive effect of intrathecal ginsenosides through α-2 adrenoceptors in the formalin test of rats
CN101472571A (zh) 使用毒蕈碱型受体m1拮抗剂治疗心理学病况
Werner et al. Supportive pain therapy in dermatology
AU2003200404B2 (en) Noribogaine in the treatment of pain and drug addiction

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: BIOTIE THERAPIES, US

Free format text: OLD OWNER(S): SYNOSIA THERAPEUTICS

PSEA Patent sealed
RENW Renewal (renewal fees accepted)
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2016 BY CPA GLOBAL

Effective date: 20150626

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2017 BY CPA GLOBAL

Effective date: 20160624

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2018 BY CPA GLOBAL

Effective date: 20170622

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2019 BY CPA GLOBAL

Effective date: 20180628

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2020 BY CPA GLOBAL

Effective date: 20190620

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2021 BY CPA GLOBAL

Effective date: 20200625

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 06 AUG 2022 BY CPA GLOBAL

Effective date: 20210624

LAPS Patent lapsed